Lung Cancer and Erlotinib: Which Patients Benefit
One of the most promising recent developments in cancer medicine has been the dramatic responses of some patients with lung cancer to the drugs gefitinib (Iressa) and erlotinib (Tarceva). Although only about 10 percent of patients with lung cancer respond in this way, a larger group experiences prolonged survival and an improvement in symptoms. Unfortunately, the best way to identify candidates for these drugs, called EGFR tyrosine kinase inhibitors (TKIs), is not yet clear.
This entry was posted on Tuesday, October 21st, 2008 at 3:15 pm and is filed under Research, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.